Lin Quek

Lin Quek has an extensive work experience spanning over several years in various roles and companies. Their most recent role is as the Associate Director of Gene Therapy Research at Fractyl Health since 2023. Prior to that, Lin worked as the Principal Scientist at Frontera Therapeutics, where they led AAV gene therapy research and collaborated with key opinion leaders and investor partners. They also served as the Business Development Manager at Genesis Biotechnology Group, achieving significant sales growth for Comparative Biosciences. Lin held leadership positions at startups such as Droplette and Novopyxis, leading gene therapy programs and contributing to IP filing and FDA applications. They also have academic research experience as a Postdoctoral Associate at the Massachusetts Institute of Technology and a Ph.D. Candidate at Johns Hopkins University. Lin has a background in biology and extensive experience in gene therapy research, drug design, preclinical through clinical R&D services, and direct marketing campaigns. Lin Quek has a Doctor of Philosophy (PhD) degree in Cellular, Molecular, Developmental Biology and Biophysics from The Johns Hopkins University. They also hold a Bachelor of Science (B.Sc.) degree in Genetics and Economics from the University of Wisconsin-Madison.